 Print page |
 Email page |
| FOR IMMEDIATE RELEASE |
September 23, 2009 |
Contact: Randolph Fillmore (813) 850-7614 rfillmore@nasw.org
ATA/ITOG Panel Discussion with FDA Participation
Design and Implementation of Thyroid Cancer Trials
(FALLS CHURCH, Sept. 23, 2009) — During the American Thyroid Association’s (ATA) 80th Annual Meeting September 23-27, 2009, held at The Breakers Hotel in Palm Beach, Florida, an ATA/ITOG Panel Discussion, with FDA participation, will be held on the “Design and Implementation of Thyroid Cancer Trials.”
Presentations include:
- “Matching Clinical Science and Regulatory Science for Improving the Care of Patients with Advanced Thyroid Cancer,” Robert Kane, FDA.
- “Current Clinical Trials on Differentiated Thyroid Cancer: Design, Endpoints, Analysis,” R. Michael Tuttle, Memorial Sloan Kettering Cancer Center.
- “Current Clinical Trials on Medullary Thyroid Cancer: Design, Endpoints, Analysis,” Robert Gagel, University of Texas M.D. Anderson Cancer Center.
The Presentations and Panel Discussion will be held Saturday, Sept. 26 from 5:45 p.m. to 7:45 p.m.
Panelist include:
- Kenneth Burman, MD, president of the ATA and chief of the Endocrine Section, Washington Hospital Center and professor, Department of Medicine, Georgetown University.
- Douglas W. Ball, MD, associate professor of medicine and oncology at the Johns Hopkins School of Medicine and associate program director for the Division of Endocrinology and Metabolism.
- Marcia S. Brose, MD, PhD, assistant professor of otorhinolaryngology at the Abramson Cancer Center at the University of Pennsylvania.
- David S. Cooper, MD, professor of medicine at the Johns Hopkins University School of Medicine and director of the Johns Hopkins Thyroid Clinic.
- Robert F. Gagel, MD, professor and head of the Division of Internal Medicine at the University of Texas M.D. Anderson Cancer Center.
- Jacqueline Jonklaas, MD, PhD, assistant professor of medicine at Georgetown University Medical Center.
- Robert C. Kane, MD, senior medical reviewer in the office of Oncology Drug Products, Center for Drug Evaluation and Research, FDA.
- Richard T. Kloos, MD, professor in the Divisions of Endocrinology and Metabolism, and Nuclear Medicine at the Ohio State University.
- Karen Murray Mahoney, MD, senior clinical reviewer in the Division of Metabolism and Endocrinology Products at the FDA.
- Ernest L. Mazzaferri, MD, emeritus professor of medicine and physiology and former chief of Endocrinology and chair of Internal Medicine at the Ohio State University.
- Matthew D. Ringel, MD, professor of medicine in the Division of Endocrinology at the Ohio State University.
- Manisha Shah, MD, associate professor of internal medicine in the Division of Hematology/Oncology at the Ohio State University.
- Steven I. Sherman, MD, professor and chair of the Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine at the University of Texas M.D. Anderson Cancer Center.
- Robert C. Smallridge, MD, professor of medicine at Mayo Clinic College of Medicine and chair of the Endocrinology Division at the Mayo Clinic Florida.
- R. Michael Tuttle, MD, a member at the Memorial Sloan Kettering Cancer Center and professor of medicine at the Joan and Sanford I. Weill Medical College of Cornell University.
Audience questions and comments will follow.
#
The American Thyroid Association (ATA) is the lead organization in promoting thyroid health and understanding thyroid biology. The ATA values scientific inquiry, clinical excellence, public service, education, collaboration, and collegiality.
A non-profit medical society founded in 1923, the ATA fulfills its mission through supporting excellence and innovation in research, clinical care, education, and public health. ATA members are physicians and scientists who work to enhance the understanding of thyroid physiology and pathophysiology, improve the diagnosis and treatment of thyroid diseases, and promote the education of physicians, patients, and the public about thyroid disorders. The official journal “Thyroid” of the ATA is published monthly. “Clinical Thyroidology” is published online monthly for the benefit of clinicians and scientists around the world.
Thyroid diseases are among the most common disorders of the endocrine system, affecting almost 13 million Americans alone. The ATA has extensive online information for patients on thyroid disease (in English and Spanish) serving the clinician as a resource for patients and the public who look for reliable information on the Internet. To further benefit patients, the ATA publishes an online journal “Clinical Thyroidology for Patients.” The Alliance for Patient Education was formed in 2002 to offer an exchange of information between the ATA and patient education groups: ThyCa: Thyroid Cancer Survivors’ Association, Inc.; the Light of Life Foundation, and the Graves’ Disease Foundation. A public forum is held each year in conjunction with the ATA annual meeting.
# # #
The 80th Annual Meeting of the ATA will be in Palm Beach, Florida, from September 23-27, 2009 at The Breakers Hotel. All registration and program information is available at www.thyroid.org. We welcome your participation.
# # #
ATA 6066 Leesburg Pike, Suite 550, Falls Church, VA 22041 * (703) 998-8890 (Fax) (703) 998-8893 * www.thyroid.org
